Latest News

The decision follows results from the Phase 3 STAR trial, among the largest global studies of low-dose atropine in pediatric myopia.

Innovations in surgery, biologics, and AI are shaping the future of eye aesthetics.

Their discussion sheds light on the importance of physician advocacy in ophthalmology—from shaping policy and protecting patients to building community.

HELIOS Phase 1 showed consistent reductions in retinal fluid with OTX-TKI, paving the way for pivotal HELIOS-2 and HELIOS-3 trials.

Inder Paul Singh, MD, shares a formative experience in which a patient’s vision loss—and their unexpected gesture of comfort—shaped his approach to high-risk glaucoma care.

A study reveals that systemic chemotherapy significantly reduces mortality in retinoblastoma, while targeted treatments lower enucleation rates.

How pupil modulation and pharmacologic targeting shape near vision outcomes.

New research reveals subretinal drusenoid deposits in Black and Hispanic AMD patients may signal higher vascular disease risk

SriniVas R. Sadda, MD, FARVO, recalls a residency case that highlights the transformative impact of OCT and OCT angiography.

AMD treatment may become unrecognizable as gene therapies evolve.

Rajpal shares his perspectives on the newly FDA-approved treatment, clinical benefits, and its potential impact on keratoconus management.

The CNPV program was announced by the FDA in June 2025 and offers companies the opportunity to reduce standard application review times from 10–12 months to just 1–2 months.